|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kamal Y, Schmit SL, Hoehn HJ, Amos CI and
Frost HR: Transcriptomic differences between primary colorectal
adenocarcinomas and distant metastases reveal metastatic colorectal
cancer subtypes. Cancer Res. 79:4227–4241. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rashid M, Vishwakarma RK, Deeb AM, Hussein
MA and Aziz MA: Molecular classification of colorectal cancer using
the gene expression profile of tumor samples. Exp Biol Med
(Maywood). 244:1005–1016. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abdul Aziz NA, Mokhtar NM, Harun R, Mollah
MM, Mohamed Rose I, Sagap I, Mohd Tamil A, Wan Ngah WZ and Jamal R:
A 19-Gene expression signature as a predictor of survival in
colorectal cancer. BMC Med Genomics. 9:582016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen H, Sun X, Ge W, Qian Y, Bai R and
Zheng S: A seven-gene signature predicts overall survival of
patients with colorectal cancer. Oncotarget. 8:95054–95065. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wolchok JD, Chiarion-Sileni V, Gonzalez R,
Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D,
Ferrucci PF, et al: Overall survival with combined nivolumab and
ipilimumab in advanced melanoma. N Engl J Med. 377:1345–1356. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cohen EEW, Soulières D, Le Tourneau C,
Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R,
et al: Pembrolizumab versus methotrexate, docetaxel, or cetuximab
for recurrent or metastatic head-and-neck squamous cell carcinoma
(KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet.
393:156–167. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y,
Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK,
et al: Pembrolizumab as second-line therapy for advanced urothelial
carcinoma. N Engl J Med. 376:1015–1026. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ,
Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill
A, et al: Durable clinical benefit with nivolumab plus ipilimumab
in DNA mismatch repair-deficient/microsatellite instability-high
metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Motzer RJ, Rini BI, McDermott DF, Arén
Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B,
Beuselinck B, Amin A, et al: Nivolumab plus ipilimumab versus
sunitinib in first-line treatment for advanced renal cell
carcinoma: Extended follow-up of efficacy and safety results from a
randomised, controlled, phase 3 trial. Lancet Oncol. 20:1370–1385.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Asaoka Y, Ijichi H and Koike K: PD-1
blockade in tumors with mismatch-repair deficiency. N Engl J Med.
373:19792015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Van Allen EM, Miao D, Schilling B, Shukla
SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger
SM, et al: Genomic correlates of response to CTLA-4 blockade in
metastatic melanoma. Science. 350:207–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bremnes RM, Busund LT, Kilvaer TL,
Andersen S, Richardsen E, Paulsen EE, Hald S, Khanehkenari MR,
Cooper WA, Kao SC and Dønnem T: The role of tumor-infiltrating
lymphocytes in development, progression, and prognosis of non-small
cell lung cancer. J Thorac Oncol. 11:789–800. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rooney MS, Shukla SA, Wu CJ, Getz G and
Hacohen N: Molecular and genetic properties of tumors associated
with local immune cytolytic activity. Cell. 160:48–61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu Y, Gaedcke J, Emons G, Beissbarth T,
Grade M, Jo P, Yeager M, Chanock SJ, Wolff H, Camps J, et al:
Colorectal cancer susceptibility loci as predictive markers of
rectal cancer prognosis after surgery. Genes Chromosomes Cancer.
57:140–149. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tripathi MK, Deane NG, Zhu J, An H, Mima
S, Wang X, Padmanabhan S, Shi Z, Prodduturi N, Ciombor KK, et al:
Nuclear factor of activated T-cell activity is associated with
metastatic capacity in colon cancer. Cancer Res. 74:6947–6957.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Allen WL, Dunne PD, McDade S, Scanlon E,
Loughrey M, Coleman H, McCann C, McLaughlin K, Nemeth Z, Syed N, et
al: Transcriptional subtyping and CD8 immunohistochemistry
identifies poor prognosis stage II/III colorectal cancer patients
who benefit from adjuvant chemotherapy. JCO Precis Oncol.
2018:2018.
|
|
25
|
Thorsson V, Gibbs DL, Brown SD, Wolf D,
Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy
JA, et al: The immune landscape of cancer. Immunity.
48:812–830.e14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gaujoux R and Seoighe C: A flexible R
package for nonnegative matrix factorization. BMC Bioinformatics.
11:3672010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao Y and Church G: Improving molecular
cancer class discovery through sparse non-negative matrix
factorization. Bioinformatics. 21:3970–3975. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Devarajan K: Nonnegative matrix
factorization: An analytical and interpretive tool in computational
biology. PLoS Comput Biol. 4:e10000292008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liberzon A, Subramanian A, Pinchback R,
Thorvaldsdottir H, Tamayo P and Mesirov JP: Molecular signatures
database (MSigDB) 3.0. Bioinformatics. 27:1739–1740. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schrock AB, Ouyang C, Sandhu J, Sokol E,
Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, et al: Tumor
mutational burden is predictive of response to immune checkpoint
inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol.
30:1096–1103. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Birkbak NJ, Kochupurakkal B, Izarzugaza
JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson
AL, Iglehart JD and Wang ZC: Tumor mutation burden forecasts
outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One.
8:e800232013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zeng Z, Vo AH, Mao C, Clare SE, Khan SA
and Luo Y: Cancer classification and pathway discovery using
non-negative matrix factorization. J Biomed Inform. 96:1032472019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang Z and Michailidis G: A non-negative
matrix factorization method for detecting modules in heterogeneous
omics multi-modal data. Bioinformatics. 32:1–8. 2016.PubMed/NCBI
|
|
38
|
Eng SWM, Aeschlimann FA, van Veenendaal M,
Berard RA, Rosenberg AM, Morris Q and Yeung RSM; ReACCh-Out
Research Consortium, : Patterns of joint involvement in juvenile
idiopathic arthritis and prediction of disease course: A
prospective study with multilayer non-negative matrix
factorization. PLoS medicine. 16:e10027502019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Carbone DP, Reck M, Paz-Ares L, Creelan B,
Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F,
et al: First-line nivolumab in stage IV or recurrent non-small-cell
lung cancer. N Engl J Med. 376:2415–2426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yarchoan M, Hopkins A and Jaffee EM: Tumor
mutational burden and response rate to PD-1 inhibition. N Engl J
Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Billingsley CC, Cohn DE, Mutch DG,
Stephens JA, Suarez AA and Goodfellow PJ: Polymerase ε (POLE)
mutations in endometrial cancer: Clinical outcomes and implications
for Lynch syndrome testing. Cancer. 121:386–394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gridelli C, Ardizzoni A, Barberis M,
Cappuzzo F, Casaluce F, Danesi R, Troncone G and De Marinis F:
Predictive biomarkers of immunotherapy for non-small cell lung
cancer: Results from an Experts Panel Meeting of the Italian
Association of Thoracic Oncology. Transl Lung Cancer Res.
6:373–386. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kudryavtseva AV, Lukyanova EN, Kalinin DV,
Zaretsky AR, Pokrovsky AV, Golovyuk AL, Fedorova MS, Pudova EA,
Kharitonov SL, Pavlov VS, et al: Mutational load in carotid body
tumor. BMC Med Genomics. 12 (Suppl 2):S392019. View Article : Google Scholar
|
|
45
|
Narayanan S, Kawaguchi T, Peng X, Qi Q,
Liu S, Yan L and Takabe K: Tumor infiltrating lymphocytes and
macrophages improve survival in microsatellite unstable colorectal
cancer. Sci Rep. 9:134552019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mirjolet C, Charon-Barra C, Ladoire S,
Arbez-Gindre F, Bertaut A, Ghiringhelli F, Leroux A, Peiffert D,
Borg C, Bosset JF and Créhange G: Tumor lymphocyte immune response
to preoperative radiotherapy in locally advanced rectal cancer: The
LYMPHOREC study. Oncoimmunology. 7:e13964022018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Glaire MA, Domingo E, Sveen A, Bruun J,
Nesbakken A, Nicholson G, Novelli M, Lawson K, Oukrif D, Kildal W,
et al: Tumour-infiltrating CD8(+) lymphocytes and colorectal cancer
recurrence by tumour and nodal stage. Br J Cancer. 121:474–482.
2019. View Article : Google Scholar : PubMed/NCBI
|
